Research programme: diabetes therapy - MediGene Ltd

Drug Profile

Research programme: diabetes therapy - MediGene Ltd

Alternative Names: HiDex

Latest Information Update: 30 Aug 2010

Price : $50

At a glance

  • Originator Avidex
  • Developer MediGene Ltd
  • Class
  • Mechanism of Action Immunomodulators; T lymphocyte inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No

Highest Development Phases

  • Discontinued Type 1 diabetes mellitus

Most Recent Events

  • 29 Sep 2006 Avidex has been acquired by MediGene AG
  • 01 Nov 2005 Preclinical trials in Type-1-diabetes-mellitus in United Kingdom (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top